Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, and Division of Gastroenterology, Omiya Medical Center, Jichi Medical Unviersity, Saitama, Japan.
Hepatol Res. 2007 Dec;37(12):1062-7. doi: 10.1111/j.1872-034X.2007.00166.x. Epub 2007 Jul 1.
It has been reported that host defense responses, such as phagocytic function of neutrophils and natural killer (NK) cell activity of lymphocytes, are impaired in cirrhotic patients. The aim of the present study was to examine the effects of oral supplementation of branched-chain amino acids (BCAA) on host defense mechanisms in peripheral blood of patients with decompensated cirrhosis.
Ten patients with decompensated cirrhosis received 12 g BCAA daily for 3 months. Phagocytic function of neutrophils and NK activity of lymphocytes as well as serum albumin levels and Fisher's ratios were determined before and at 1 and 3 months of BCAA supplementation. For quantification of phagocytic function, fluorescent intensities of cells in the neutrophil region in the cytogram were determined by flow cytometry after incubation of whole blood with fluorescent microspheres. NK activity was estimated by (51)Cr release assay using K-562 cell line as target cells.
Phagocytic function of neutrophils was significantly improved by 3-month BCAA supplementation (P < 0.01). Thechanges of NK activity were also significant at 3 months of supplementation compared with before supplementation (P < 0.01). Fisher's ratios were significantly increased at 3 months of BCAA supplementation compared with those before oral supplementation (P < 0.05), although the changes of serum albumin level were not statistically significant.
BCAA oral supplementation improved phagocytic function of neutrophils and NK activity of lymphocytes in cirrhotic patients. BCAA supplementation may reduce the risk of bacterial and viral infection in patients with decompensated cirrhosis.
据报道,肝硬化患者的宿主防御反应(如中性粒细胞的吞噬功能和淋巴细胞的自然杀伤(NK)细胞活性)受损。本研究旨在探讨口服补充支链氨基酸(BCAA)对失代偿期肝硬化患者外周血宿主防御机制的影响。
10 例失代偿期肝硬化患者每天接受 12g BCAA 治疗 3 个月。在 BCAA 补充前、1 个月和 3 个月时测定中性粒细胞的吞噬功能、淋巴细胞的 NK 活性以及血清白蛋白水平和 Fisher 比值。为了定量测定吞噬功能,在全血与荧光微球孵育后,通过流式细胞术测定细胞在细胞图中中性粒细胞区域的荧光强度。使用 K-562 细胞系作为靶细胞,通过(51)Cr 释放测定法估计 NK 活性。
3 个月的 BCAA 补充显著改善了中性粒细胞的吞噬功能(P<0.01)。NK 活性在补充 3 个月时也与补充前相比有显著变化(P<0.01)。与口服补充前相比,BCAA 补充 3 个月时 Fisher 比值显著升高(P<0.05),尽管血清白蛋白水平的变化无统计学意义。
BCAA 口服补充改善了肝硬化患者中性粒细胞的吞噬功能和淋巴细胞的 NK 活性。BCAA 补充可能降低失代偿期肝硬化患者发生细菌和病毒感染的风险。